Aims This study aimed to elucidate the molecular background of increased Ca 2+ sensitivity of force production in cardiomyocytes of end-stage human heart failure.
Introduction
Alterations in myocardial proteins (molecular remodelling) contribute to the progressive diminution of cardiac performance during end-stage heart failure. 1, 2 One of the factors involved in myocardial dysfunction is an increased myofibrillar Ca 2+ sensitivity of force production, as a result of alterations in the expression, 3, 4 and/or phosphorylation levels [5] [6] [7] of contractile proteins. Although interpretation of heart failure specific myofibrillar protein changes
O R I G I N A L R E S E A R C H A R T I C L E
is complicated by conflicting data of human hearts and of animal models, 8 it is generally accepted that downregulation of β-adrenergic signalling leads to hypophosphorylation of contractile proteins and consequently to an increased Ca 2+ sensitivity of force production during end-stage human heart failure. 9 Of note, phosphorylation statuses of contractile proteins are the function of a number of protein kinases and phosphatases, hence allowing fine tuning for contractile performance during health and disease. 8, [10] [11] [12] In this regard, reduced levels of phosphorylation for constituents of the thin filament (e.g. troponin I) and of the thick filament (e.g. myosin binding protein C, myosin light chain 2) have been consistently documented for progressed stages of human heart failure in association with ischaemic and/or dilated cardiomyopathy. 7, 13, 14 The Ca 2+ sensitivity of force production is a result of the cooperative interplay between the thin and thick filaments in striated muscles. 15, 16 Thus, it is controlled not only by the Ca 2+ regulation of the thin filaments 17 but also by the kinetic properties of the actin-myosin cross-bridge cycle. 18 The aim of this study was to reveal putative alterations in the previous two processes in order to clarify the mechanistic background of the increased Ca 2+ sensitivity of force production seen in association with endstage human heart failure. We hypothesize that changes in the chemo-mechanical transduction of the actin-myosin cross-bridge cycle is an integral element within the pathogenesis of heart failure, where protein phosphorylation plays a central mechanism.
To characterize the relationships between the Ca 2+ sensitivity and the kinetics of actin-myosin cross-bridges, the [Ca 2+ ] dependencies of isometric force production and of k tr , i.e. the cross-bridge specific rate constant of tension redevelopment after unloaded shortening and restretch, were measured simultaneously in Triton-permeabilized human left ventricular myocytes. Ca 2+ regulation was modulated by acidification, 17 while inorganic phosphate (P i ) was added to probe the force-generating cross-bridge transitions. 19 Our results indicate that kinetic alterations of the crossbridge cycle have a direct impact on the Ca 2+ sensitivity in the human myocardium and may also affect the conversion of chemical energy into force and shortening during end-stage human heart failure.
Methods

Biopsies
Left ventricular biopsies were obtained during heart transplantation surgery from three explanted end-stage failing (New York Heart Association class IV) hearts (three males, age range 45-65 years) and from three non-failing donor hearts (two males, one female; age range 23-52 years). The heart failure resulted from ischaemic or dilated cardiomyopathy. The cardiac tissue was transported in cardioplegic solution, and upon arrival in the laboratory, the tissue was stored in liquid nitrogen. Phosphorylation levels of myofibrillar proteins of failing and non-failing myocardial tissue samples are given elsewhere. 7 The investigation conforms with the principles outlined in the Declaration of Helsinki. 20 All samples were obtained after informed consent had been received and with the approval of the local ethical committees, and the procedures followed were in accordance with institutional guidelines.
Myocyte isolation
Cardiomyocytes (8-9 per biopsy, 52 in total) were isolated mechanically and mounted in the experimental set-up as described previously. 21 0.5% Triton X-100 was used to remove all the membranous structures of the myocytes. This allowed the study of myofibrillar contractile properties in the presence of a controlled intracellular environment without the presence of disturbing factors in the intact heart (i.e. hormonal factors, variable [Ca 2+ ]) or in multicellular preparations (myofibrillar disarray, diffusion limitations).
Experimental protocol
Isometric force measurements were performed at 15°C, and sarcomere length was adjusted to 2.1 μm in relaxing solution. The compositions of the relaxing and activating solutions used during force measurements were calculated as described by Fabiato (1981) . 22 The pCa levels of the control (pH 7.2, 0 mM P i ) relaxing and activating solutions were 10 and 4.8, respectively. Solutions with other free [Ca 2+ ] were obtained by mixing of the activating and relaxing solutions. After the first control activation (F o ) at saturating [Ca 2+ ] (pCa = 4.8) ( Figure 1A ), the resting sarcomere length was readjusted to 2.1 μm if necessary. The next four or five activations were carried out under various experimental conditions, followed by a bracketing control F o determination. Measurements were continued until F o had decreased below 80% of the value obtained at the beginning of the experiment. Force values at submaximal [Ca 2+ ] were expressed relative to the nearest control F o . To achieve maximal Ca 2+ activation in the presence of 10 mM P i and/or at pH 6.5, appropriate amounts of CaCl 2 were added to the activating solutions to cover a [Ca 2+ ] range up to pCa 3.3.
The rate of force redevelopment (k tr ) was determined by using release-restretch manoeuvers, as illustrated in Figure 1B . 23 At low [Ca 2+ ] (P < 25% of the control F o ), the low signal-to-noise ratio prevented k tr determination.
Data analysis
Ca 2+ -force relations were fitted to a modified Hill equation:
where F is the steady-state force at a given [Ca 2+ ], while F o , nHill, and Ca 50 (or pCa 50 ) denote the maximal Ca 2+ -activated force at saturating [Ca 2+ ], the slope, and the midpoint of the sigmoidal relationship, respectively.
All values in the text and figures are given as means ± S.E.M. Mean values were compared through unpaired Student's t-tests. Differences were considered significant when P < 0.05.
Results
The isometric force (F o ) and the rate constant of tension redevelopment (k trmax ) under control conditions (pH 7.2; 0 mM P i ) for failing (38 ± 4 kN m À2 and 1.00 ± 0.06 s À1 , respectively) and the non-failing (36 ± 3 kN m À2 and 0.93 ± 0.02 s
À1
) myocytes did not differ significantly at saturating [Ca 2+ ]. In accordance with the findings in previous studies 3, 4, 6 we observed an increased Ca 2+ responsiveness of the contractile apparatus in end-stage failing human myocardium (Figure 2A ; ΔpCa 50 = 0.15, P < 0.05). Our experiments also showed that not only the isometric force but also k tr ( Figure 2B ) in failing myocytes was markedly higher at submaximal [Ca 2+ ] (Δk tr = 0.16 s À1 at pCa 6.0) than in non-failing myocytes.
Modulation of the cross-bridge function by adding 10 mM P i decreased force at saturating [Ca 2+ ] to a similar extent (to 41 ± 2 and 40 ± 1% respectively) in the failing and non-failing myocytes. P i induced a rightward shift in the Ca 2+ -force relationship, which was, however, significantly larger for the failing myocytes than for the nonfailing myocytes. This completely eliminated the initial difference in Ca 2+ sensitivity between the failing and non-failing myocytes (Figure 2A) .
Modulation of the thin filament Ca 2+ -sensory function by reducing the pH of the solutions from 7.2 to 6.5 caused a similar decline in F o (to 54 ± 4 and 59 ± 3%, respectively) in the failing and non-failing myocytes and also shifted the Ca 2+ sensitivity relations of the failing and non-failing myocytes in an almost identical manner. However, also at pH 6.5, the addition of 10 mM P i abolished the difference in the Ca 2+ -force relations of the failing and non-failing myocytes, (Figure 2A ). An overview of the parameters describing the Ca 2+ -force relations is given in Table 1 . P i caused a marked increase in k trmax both in the failing and in the non-failing myocytes (from 1.00 ± 0.06 and 0.93 ± 0.02 s À1 to 1.97 ± 0.09 and 2.22 ± 0.11 s
, respectively; P < 0.05) ( Figure 2B ). However, there was one conspicuous difference: the P i -induced increase in k tr for the failing myocytes at submaximal [Ca 2+ ] was significantly less than that for the non-failing myocytes. Acidosis increased k trmax by~30% in both groups (to 1.28 ± 0.08 and 1.32 ± 0.12 s À1 in the failing and non-failing myocytes, respectively). Determination of k tr at pH 6.5 was feasible only between pCa 3.5 and pCa 4.71 and in the absence of P i . In these cases, no significant difference in k tr was observed between the failing and non-failing myocytes.
Discussion
This study clearly shows the following: (1) the difference in the Ca 2+ sensitivities of force production between failing and non-failing myocardium is eliminated by 10 mM P i . (2) P i causes a smaller acceleration of the cross-bridge kinetics in the failing than in the non-failing myocytes, whereas modulation of the Ca 2+ -regulatory function of the thin filament affects force generation similarly in failing and non-failing hearts.
In our previous studies, we have shown that the increased Ca 2+ responsiveness in failing human hearts most likely results from deceased phosphorylation of myosin light chain 2 and troponin I, in particular bisphosphorylation of serines 23 and 24. 23 However, we did not observe a difference in myosin light chain 1 and troponin T phosphorylation between donor and failing hearts. 7, 13 In this study, our primary aim was to explore the molecular background of the altered cardiac pump function during end-stage human heart failure. To obtain a more detailed picture, the determination of Ca 2+ -force relation was paralleled by k tr measurements in the absence or presence of ischaemic metabolites.
Acidification reduced pCa 50 and the cooperativity (nHill) of force production both in the failing and in the non-failing myocytes, while the increase in k trmax was small. These findings are consistent with the notion that the pH has a major impact on the Ca 2+ -binding function of troponin C but has little direct effect on the transitions between the weak and strong cross-bridge states. 17 10 mM P i reduced F o more than acidosis, but it induced a smaller rightward shift in the calcium-force relations and did not change the Hill coefficient either in the failing or in the non-failing myocytes. These alterations, together with the large increase seen in k tr , are in agreement with the view that P i , via reducing the overall free energy of MgATP hydrolysis, affects the cross-bridges directly 19, 24, 25 and has no direct effect on the Ca 2+ -binding function of troponin C. 17 It is now generally accepted from animal studies that P i reverses the P i -release step of the cross-bridge cycle by mass action, thereby decreasing the proportion of crossbridges in the high-force conformation. 19, [24] [25] [26] Furthermore, the P i -induced changes in pCa 50 are considered to be a consequence of the altered distribution of actin-myosin states within the cross-bridge cycle. 17 An elevation in the rate of the cross-bridge transition from the non-force-generating state to the forcegenerating state (f app ) increases pCa 50. 18 Under control conditions, the higher k tr (f app + g app ) values of the failing myocardial cells are thus logically related with the observed increase in pCa 50 . Reduction of the pH from 7.2 to 6.5 evoked comparable reductions in the Ca 2+ sensitivities of force production and-with respect to k tr -it also did not discriminate between the failing and the non- failing myocytes. These observations suggest that the thin filament regulation during human heart failure is not intrinsically altered despite a probable reduction in the level of troponin I phosphorylation. 5, 7 In contrast, the P i sensitivity of pCa 50 and k tr differed significantly between the failing and the non-failing myocytes. P i decreased pCa 50 more, whereas it increased the Ca 2+ sensitivity of k tr less in the failing myocytes than in the non-failing myocytes. It is concluded, therefore, that the molecular interplay between cross-bridge transitions and the Ca 2+ sensitivity of force production is characteristically altered in the failing human heart. This most likely involves the chemo-mechanical transduction process per se through a reduction in the rate of the P i -release step and/or enhancement of the reverse reaction. The elimination of the higher Ca 2+ sensitivity of force production by 10 mM P i in the failing myocytes occurred both at pH 7.2 and at pH 6.5, in perfect agreement with the notion that the P i effect is independent from that of protons.
24,27
Functional implications
The F o and k trmax values at saturating [Ca 2+ ] of failing and non-failing human myocytes did not differ significantly from each other under any metabolic conditions and thus corroborated previous findings of our group. 27 During physiological cardiac activity, the thin filaments are far from Ca 2+ saturation. Differences in the mechanical parameters of failing and non-failing hearts at intermediate [Ca 2+ ] therefore bear important functional consequences for the cardiac performance. The increase in the apparent Ca 2+ sensitivity of force production might be deleterious for the diastolic function, but it could potentially compensate for the reduced amplitude of the Ca 2+ transient during systole. Here, we show that the disturbance in cross-bridge cycling is coupled to an enhanced P i dependence of Ca 2+ sensitivity in failing myocardium. Hence, P i accumulation, e.g. during ischaemia, may eliminate the advantage of an increased Ca 2+ reactivity.
Moreover, slowing of the P i -release step might explain the increased economy of contraction observed in failing hearts. 26 Nevertheless, it is to be acknowledged that end-stage heart failure is a complex syndrome, where in addition to alterations of sarcomeric proteins in cardiomyocytes, pump function may also depend on the largely unknown interplay of numerous cell types in the myocardium.
Recent pharmacological research resulted in the development of so-called direct myosin activator agents for the management of systolic heart failure. 28 These drugs bind to the myosin catalytic domain and operate by an allosteric mechanism through the modulation of P i -dependent myosin function. In animal models of heart failure, cardiac myosin activation gave promising results, while in humans, convincing results are still awaited. 29 Our present results imply that the eventual success of new sarcomere targeted agents will depend not only on their pharmacokinetic binding characteristics to a well-defined target molecule but rather on their complex action on the actin-myosin cross-bridge cycle during human heart failure. 
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